<DOC>
	<DOC>NCT03073213</DOC>
	<brief_summary>The purpose of the study is to research how much ixekizumab enters the bloodstream and how long the body takes to get rid of the drug and the safety of ixekizumab and any side effects that might be associated with it. The study has two parts: A single-dose part and multiple-dose part. The single dose part of this study will last up to 24 weeks, including the screening period. The multiple dose part of this study will last up to 32 weeks including the screening period.</brief_summary>
	<brief_title>A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male or female participants with chronic plaque psoriasis (greater than or equal to 10 percent (%) body surface area (BSA); static Physician's Global Assessment (sPGA) score of greater than or equal to 3 and Psoriasis Area and Severity Index (PASI) score greater than or equal to 12) at least 6 months before baseline Have a body mass index between 18 and 35 kilogram per meter square (kg/mÂ²) Previously completed or withdrawn from an ixekizumab study or a study investigating interleukin17 (IL17) antagonists Have an active or recent infection or a compromised immune system Have active or dormant tuberculosis Have a serious or unstable/uncontrolled illness, including heart disease, abnormal blood pressure, mental disorder, malignancy or other disease Be pregnant or breastfeeding Had any major surgery within 8 weeks prior to baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>